glp-1 nobel prize GLP-1-based therapy for obesity The Nobel Prize season kicks

Cost and access matter, too

Modern software must bridge the gap between medication and continuous biometric data

Discussion While GLP-1 RAs are powerful anti-obesity medications (AOMs), they do raise some serious concerns most notably, up to 40% of the profound weight loss induced by these agents can be due to loss of lean mass 3,4,5 and prior studies have shown that a significant portion of this lean mass is muscle 33,34,35

the release is low when fasted and increases during all phases of digestion (55, 56)

Kilgore KP, Lee MS, Leavitt JA et al (2017) Re-evaluating the incidence of idiopathic intracranial hypertension in an era of increasing obesity